Psoriasis (Auckland, N.Z.)最新文献

{"title":"TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses.","authors":"Bowen Dai, Ye Tang, Bin Zhang, Guangyao Xu, Yanan Zhang, Kan Ze","doi":"10.2147/PTT.S535434","DOIUrl":"10.2147/PTT.S535434","url":null,"abstract":"<p><strong>Background: </strong>Genetic susceptibility to psoriasis involves multiple loci, including TYK2 (Tyrosine Kinase 2), which is associated with various autoimmune diseases. However, its specific role and mechanisms in psoriasis remain unclear. This study aimed to identify psoriasis-associated proteins using Summary-based Mendelian Randomization (SMR) and to explore their regulatory mechanisms.</p><p><strong>Methods: </strong>SMR analysis integrating pQTL data was conducted to identify proteins linked to psoriasis, revealing ICAM1 (Intercellular Adhesion Molecule 1) as a potential pathogenic factor. A key SNP, rs34536443 (P1104A), located in TYK2, was found to regulate ICAM1. To assess its function, THP-1 cells carrying the TYK2-P1104A mutation were generated, and ICAM1 and cytokine expression were analyzed following LPS stimulation. The effect of the TYK2 inhibitor Deucravacitinib was tested in an imiquimod (IMQ)-induced psoriasis mouse model.</p><p><strong>Results: </strong>SMR identified ICAM1 as a causal protein for psoriasis, regulated by the TYK2 SNP rs34536443. In TYK2-P1104A mutant THP-1 cells, LPS-induced ICAM1 expression was significantly reduced, with ICAM5 unaffected. The mutation also suppressed IL-1β, TNF-α, IL-6, and IL-18 expression, suggesting anti-inflammatory effects. Single-cell RNA-seq revealed enrichment of TYK2, ICAM1, and ICAM5 in dendritic cells and monocytes. In vivo, Deucravacitinib significantly downregulated ICAM1 in the IMQ-induced psoriasis model, with minimal effect on ICAM5.</p><p><strong>Conclusion: </strong>This study identifies ICAM1 as a key mediator in psoriasis via SMR analysis and implicates the TYK2 SNP rs34536443 in its regulation. The TYK2-P1104A variant attenuates ICAM1 and cytokine expression, and Deucravacitinib downregulates ICAM1 in vivo. These findings provide mechanistic insights into the TYK2-ICAM1 axis and support the therapeutic potential of TYK2 inhibitors for psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"361-372"},"PeriodicalIF":5.2,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12357608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144877200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimekizumab: The First FDA-Approved Dual IL-17A/IL-17F Inhibitor for Plaque Psoriasis - A Comprehensive Literature Review.","authors":"Sukainah Ahmed Al Alshaikh, Zahra Mohammad Almarhoon, Hisham Momattin, Mahdi Aleid, Zahra H Almousa, Ali Kamal Alqaisum, Fatimah Ismail Mobarki, Sarah Aon Almakki, Hamzah Alturfi, Kouther Jamil Almajed","doi":"10.2147/PTT.S544166","DOIUrl":"10.2147/PTT.S544166","url":null,"abstract":"<p><p>Psoriasis is a chronic inflammatory immune-mediated disease that affects 1-3% of the worldwide population. It is now known that interleukin IL-17F and IL-17A have a role in the pathophysiology of immune-mediated inflammatory disorders, such as psoriasis. According to recent data, neutralizing IL-17A and -17F together may be more effective than neutralizing IL-17A alone in treating psoriasis. Bimekizumab is a humanized IgG1 monoclonal antibody that selectively binds and diminishes the biological functions of both IL-17A and -17F. Current biologics for treating psoriasis lack complete skin clearance and reliable quick response. Bimekizumab's efficacy was evaluated in four randomized controlled trials involving around 2,200 patients with plaque psoriasis. The results showed that bimekizumab outperformed placebo, adalimumab, secukinumab, and ustekinumab, with higher response rates for both PASI 90 and PASI 100 at 16 weeks. Furthermore, Bimekizumab has shown superiority in direct comparative clinical studies (RCTs) performed. When compared to other biologics, Bimekizumab has shown a more rapid onset in terms of rapid response and better efficacy with a comparable safety profile as the most frequent adverse events include oral candidiasis, upper respiratory tract infections, and nasopharyngitis. These features of Bimekizumab provide advantages for the patients in term of better efficacy with rapid response and safe profile which ultimately affect the selection and treatment algorithm for management of plaque psoriasis.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"351-360"},"PeriodicalIF":5.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335252/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization and Costs of Laboratory Monitoring in Biological and Non-Biological Psoriasis Treatment - Large-Scale Claims Data Analysis.","authors":"Jan Nicolai Wagner, Kristina Hagenström, Katharina Sophia Müller, Brigitte Stephan, Matthias Augustin, Ralph von Kiedrowski","doi":"10.2147/PTT.S531836","DOIUrl":"10.2147/PTT.S531836","url":null,"abstract":"<p><strong>Purpose: </strong>Psoriasis vulgaris is a chronic systemic inflammatory disease that imposes a significant physical, emotional, and social burden on affected individuals. There is a growing recognition of the importance of comprehensive monitoring and management to optimize treatment outcomes, particularly with the advent of advanced systemic therapies. This study aims to characterize the prevalence of laboratory monitoring and associated costs in persons with psoriasis undergoing systemic treatment. A specific focus was placed on the differences by treatment modality, patient characteristics, and economic burden to the payers.</p><p><strong>Patients and methods: </strong>A retrospective longitudinal analysis was conducted using German health insurance data from the DAK-Gesundheit. The study population included persons diagnosed with psoriasis who received systemic therapies between 2016 and 2020. Laboratory service utilization and costs were assessed during the initiation and course of treatment, factoring in demographic parameters and comorbidities.</p><p><strong>Results: </strong>Among 62,063 persons with psoriasis, 8018 (12.9%) were identified as having received systemic treatment, which of 92.5% utilized at least one laboratory service. The average annual laboratory monitoring cost per person was higher for those on biologic therapies (57.88 €) compared to systemic treatments (23.70 €). Laboratory service utilization and costs were associated with the comorbidity index (CCI) and age.</p><p><strong>Conclusion: </strong>Biologic therapies for psoriasis induce considerably higher monitoring costs than non-biological systemic drugs. Age and CCI were main predictors for higher utilization of laboratory services, indicating a medical rationale to perform more lab screenings in risk groups for safety events. The laboratory costs add to the higher drug costs of biologicals but need to be related to the benefits from treatment. Furthermore, the monitoring costs are far lower than the drug costs and thus may not be major decision drivers.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"327-338"},"PeriodicalIF":5.2,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144818584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Tildrakizumab in Elderly and Frail Elderly Psoriatic Patients Up to 2 years.","authors":"Luca Mastorino, Paolo Dapavo, Martina Burlando, Paolo Gisondi, Carlo Alberto Maronese, Angelo Ruggiero, Marco Galluzzo, Maria Carla Pisani, Lidia Sacchelli, Giacomo Caldarola, Gianluca Avallone, Angelo Valerio Marzano, Matteo Megna, Elena Campione, Francesco Loconsole, Federico Bardazzi, Clara De Simone, Pietro Quaglino, Simone Ribero","doi":"10.2147/PTT.S525256","DOIUrl":"10.2147/PTT.S525256","url":null,"abstract":"<p><strong>Purpose: </strong>Elderly patients with age ≥65 years represent an increasing percentage of the population with moderate-severe psoriasis. The definition of \"frail elderly\" is not easily framed, generally meaning a patient with unstable homeostasis. To date, there is no study in the literature examining possible differences between frail and non-frail elderly with psoriasis being treated with tildrakizumab.</p><p><strong>Patients and methods: </strong>The present multicentre retrospective study evaluated the effectiveness, drug survival and safety up to 2 years of treatment with tildrakizumab in the elderly (≥65 years) comparing frail and non-frail patients. Frail patients were defined as those with: i) 2 major comorbidities, or 1 major comorbidity and low economic level ii) and/or 2 of the following 5 parameters: weight loss, weakness, sluggishness, low activity level, and exhaustion.</p><p><strong>Results: </strong>A total of 217 patients aged ≥65 years were enrolled, of whom 89 (41%) were grouped in the frail patient category. In the entire population, 2-year drug survival was ≥80%, and PASI 90 and ≤2 was achieved in 75% and 87.5% of patients, respectively. No difference in effectiveness or safety was found between frail and non-frail populations. Adjusting for baseline characteristics at Cox-regression, frail patients did not show a greater risk of discontinuation (HR 0.51, p=0.091).</p><p><strong>Conclusion: </strong>Tildrakizumab showed good safety and effectiveness at 2 years in the elderly population with or without frailty, confirming it as a possible treatment of choice in psoriatic patients with significant comorbidities and older frail patients who deserve systemic treatments.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"339-350"},"PeriodicalIF":5.2,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144823303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis.","authors":"Yu Xiao, Jingru Sun","doi":"10.2147/PTT.S536639","DOIUrl":"10.2147/PTT.S536639","url":null,"abstract":"<p><p>Moderate to severe psoriasis has been reported as an independent risk factor for IgA nephropathy (IgAN). IgAN is characterized by episodic microscopic hematuria, which can progress to end-stage renal disease (ESRD). Managing therapeutic interventions for psoriasis patients requiring dialysis due to ESRD presents significant challenges. We present a case of severe plaque psoriasis in a patient concurrently diagnosed with IgAN who is dependent on hemodialysis. Over the past two months, his condition has worsened without any identifiable triggers. Physical examination revealed generalized scaly plaques on the scalp, trunk, and extremities, resulting in a Psoriasis Area Severity Index (PASI) score of 19.2. Laboratory tests confirmed end-stage renal insufficiency, with no other abnormalities detected. Consequently, the patient was prescribed subcutaneous secukinumab following a standard regimen. He achieved complete resolution of symptoms after eight weeks of treatment and experienced no recurrence during a one-year follow-up. His kidney-related parameters remained stable during secukinumab therapy. To summarize, this case report discusses a patient with severe psoriasis who also has concurrent IgAN and ESRD, successfully treated with secukinumab. It reinforces the rapid efficacy and enduring safety of secukinumab in managing psoriasis in hemodialysis-dependent patients with IgAN comorbidity. Zeno Fratton et al has reported that an interleukin (IL)-17A/F inhibitor effectively treats moderate-to-severe psoriasis in patients with chronic kidney disease (CKD). However, further studies are necessary to develop evidence-based guidelines for biologic selection within this vulnerable population.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"321-325"},"PeriodicalIF":5.2,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296631/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144735866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on Erythrodermic Psoriasis: Proposal of a Management Algorithm by an Innovative Severity Evaluation Approach.","authors":"Jia-Ming Xu, Chao Wu, Hao Feng, Hong-Zhong Jin","doi":"10.2147/PTT.S532062","DOIUrl":"10.2147/PTT.S532062","url":null,"abstract":"<p><p>Erythrodermic psoriasis (EP) is an uncommon and severe form of psoriasis, which exhibits a Th1/Th17/TNF inflammatory pattern. Most patients with EP experience systemic symptoms that necessitate systemic treatments. These treatments include conventional systemic drugs (such as acitretin, cyclosporin A, and methotrexate), biologics (including IL-17, IL-12/23, and TNF-α inhibitors), and small molecule drugs (such as apremilast and JAK inhibitors). Evaluating the severity of EP is critical for determining appropriate treatment strategies. According to an innovative EP severity evaluation approach, patients exhibiting two or more clinical features-fever, exudation, or lymphadenopathy-are classified as having moderate-to-severe EP, while those with one or none of these symptoms are categorized as having mild EP. Mild EP can often be managed with monotherapy using acitretin, methotrexate, or biologics, such as IL-17 or IL-12/23 inhibitors, excluding TNF-α inhibitors. For moderate-to-severe EP, cyclosporine A and biologics, particularly IL-17 or IL-12/23 inhibitors, are recommended. Combination therapies are considered when monotherapies prove ineffective. These may involve combining a biologic with a conventional systemic drug or using two to three conventional systemic drugs together to enhance efficacy. Supportive care plays a critical role in alleviating the discomfort associated with skin lesions and other complications. Additionally, treatments should be tailored to address specific comorbidities, often requiring multidisciplinary collaboration. In our comprehensive review, we summarized the current evidence on therapeutic options for EP, including details on dosages, treatment durations, efficacy, and adverse events. Additionally, we incorporated new evidence on the use of acitretin, biologics, and JAK inhibitors for EP. We also introduced, for the first time, a practical management algorithm based on severity evaluation to guide the appropriate treatment of EP.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"301-320"},"PeriodicalIF":5.2,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12285892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144700641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriasis Does Not Seem to Impair Glomerular and Tubular Function - The Comprehensive Study on Serum and Urine.","authors":"Julia Nowowiejska, Anna Baran, Justyna Magdalena Hermanowicz, Beata Sieklucka, Olga Martyna Koper-Lenkiewicz, Joanna Kamińska, Krystyna Pawlak, Dariusz Pawlak, Iwona Flisiak","doi":"10.2147/PTT.S530313","DOIUrl":"10.2147/PTT.S530313","url":null,"abstract":"<p><strong>Introduction: </strong>There is a dispute as to whether patients with psoriasis have impaired kidney function. We aimed to assess several recognized and experimental markers of glomerular filtration and tubular function in such patients to find out whether they have decreased kidney function.</p><p><strong>Methods: </strong>The study involved 60 patients with psoriasis and 30 volunteers without dermatoses. The following molecules were analyzed by ELISA: serum creatinine, cystatin C, beta-trace protein, albumins, uromodulin; urinary albumins, cystatin C, alpha-1-microglobulin, beta-2-microglobulin, uromodulin, klotho, and fatty acid-binding protein 1, and nephrin.</p><p><strong>Results: </strong>The following absolute values of markers concentrations were measured in patients, respectively: serum-1.13 (0.6-1.9)mg/dl, 4.511 (2.356-10.31)mg/l, 19.8 (2.8-48)ng/mL, 4.2 (1.9-8.85)g/dl, 212.3 (32.35-583.9)ng/mL, urine-5 (3-39)g/dl, 24096 (79.94-99020)ng/mL, 0.9342 (0.2088-6.213)ng/mL, 22.65 (0.85-105.8)ng/mL, 6.388 (0.8960-15.94)ng/mL, 0.08 (0.002-0.387)ng/mL, 1.773 (1.706-2.146)ng/mL, 0.128 (0.095-0.298)ng/mL. The patients had significantly lower serum albumin concentration (p<0.001) and higher urinary albumin (p<0.05), significantly higher serum cystatin C (p<0.01), and absolute urinary nephrin (p<0.05). There was no difference between patients and controls in terms of serum creatinine or beta trace protein concentration (p>0.05). There were no significant differences in the concentration of the tubular markers (urinary cystatin C, alpha-1-microglobulin, beta-2-microglobulin, klotho, and fatty acid-binding protein 1) between patients and controls, except for serum and urinary uromodulin, which were significantly lower in patients (p<0.01, p<0.001, respectively). We found no significant correlations between the investigated markers' concentration and clinical or demographic parameters (p>0.05).</p><p><strong>Discussion: </strong>Despite the differences between patients and controls in terms of glomerular filtration markers, the median values of markers' concentration were within normal limits. Based on the assessment of the markers, it does not seem that impaired glomerular and tubular function occurs more frequently in patients with psoriasis. Nevertheless, due to the higher prevalence of diabetes mellitus and arterial hypertension in psoriatics and nephrotoxic properties of antipsoriatic drugs - caution must be exercised and easy screening tools should be considered.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"285-299"},"PeriodicalIF":5.2,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12282536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144692726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and Health Care of Generalized Pustular Psoriasis in Germany - Methodology and Outcomes of Claims Data Analysis.","authors":"Kristina Hagenström, Katharina Müller, Nesrine Ben-Anaya, Matthias Augustin","doi":"10.2147/PTT.S529515","DOIUrl":"10.2147/PTT.S529515","url":null,"abstract":"<p><strong>Purpose: </strong>Epidemiological and health care data on generalized pustular psoriasis (GPP) show large differences in literature. This study assessed GPP epidemiology, comorbidities and health care in Germany.</p><p><strong>Patients and methods: </strong>Nationwide population-related German claims data were analyzed using different case definitions for internal validation.</p><p><strong>Results: </strong>In 2019, the prevalence of GPP in Germany in adults ranged from 8 to 39 and incidence from 1 to 15 persons per 100,000. Prevalence was higher in women and increased with age. Thirty-three percent had at least one other psoriatic ICD-10 code. People with GPP had significantly more skin diseases as well as cardiovascular and mental diseases than persons without psoriasis/GPP. The average annual drug costs per capita were € 2050 and were highest in those receiving biologicals (€ 15,524). Marked differences in treatment by specialist were observed.</p><p><strong>Conclusion: </strong>Acknowledging that the observed frequency or costs associated with GPP may be underestimated due to a few inherent limitations is important. Differences in GPP coding behavior and diagnostic accuracy may contribute to variations in epidemiology. The high disease burden is reflected by high annual costs and by significant comorbidity.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"273-283"},"PeriodicalIF":5.2,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12275989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tobacco Smoking Was Positively Associated with Disease Relapse at week 24 and 48 Among Patients with Psoriasis Vulgaris in Shanghai: A Prospective Study.","authors":"Fanlingzi Shen, Yuning Ding, Yan Qiang, Zhen Duan, Quanruo Xu, Xiangjin Gao, Rui Zhang, Ruiping Wang","doi":"10.2147/PTT.S534032","DOIUrl":"10.2147/PTT.S534032","url":null,"abstract":"<p><strong>Purpose: </strong>Tobacco smoking is an unhealthy behavior associated with the onset, severity, and treatment response of psoriasis. However, evidence regarding the impact of tobacco smoking on the relapse of psoriasis remains limited. This study aims to examine the relapse condition in psoriasis patients and explore the association between tobacco smoking and psoriasis relapse.</p><p><strong>Patients and methods: </strong>We conducted an observational study with 551 psoriasis patients recruited from 2022 to 2024 in Shanghai Skin Disease Hospital. A structured questionnaire and physical examination were used to collect data at baseline, week 12, week 24 and week 48. PASI50 and PASI75 were used to evaluate the improvement of psoriasis patients after treatment at week 12, and disease relapse was defined as the loss of 50% PASI improvement during clinical remission after the achievement of PASI50 or PASI75 at week 12.</p><p><strong>Results: </strong>75.7% of the 551 psoriasis patients were males, with an average age of 45.8 years, and 282 (51.2%) were tobacco smokers. 41.2% and 61.6% of psoriasis patients with PASI50 achievement at week 12 encounter disease relapsed at week 24 and 48, respectively, while for patients with PASI75 achievement at week 12, the relapse rate was 27.6% and 51.7% at week 24 and 48, respectively. Logistic regression indicated that patients with tobacco smoking had a higher relapse rate, especially among those with PASI75 achievement at week 12. The odds ratio was 2.10 (95% CI: 1.17-3.78) and 1.84 (95% CI: 1.07-3.14) at week 24 and week 48 respectively, even after adjusting for potential confounding factors. Moreover, patients with longer smoking duration and more daily cigarette consumption had higher relapse rate.</p><p><strong>Conclusion: </strong>Tobacco smoking was positively correlated with the relapse, especially among those with longer smoking duration and more daily cigarette consumption. Therefore, patients with psoriasis should quit smoking to reduce the risk of relapse.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"261-272"},"PeriodicalIF":5.2,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12273883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and Safety of Adalimumab Biosimilars in Pediatric Psoriasis: A Multi-Center International Experience.","authors":"Cristina Bertoli, Tiago Torres, Paolo Romita, Luca Stingeni, Katharina Hansel, Luca Mastorino, Michela Ortoncelli, Michele Panzone, Maria João Cruz, Luca Bianchi, Arianna Zangrilli, Maria Letizia Musumeci, Giuseppe Micali, Carlo Gerbino, Oriana Simonetti, Edoardo De Simoni, Caterina Longo, Emmanuel Mahé, Vito Di Lernia","doi":"10.2147/PTT.S514115","DOIUrl":"10.2147/PTT.S514115","url":null,"abstract":"<p><strong>Background: </strong>Many adalimumab biosimilars have been approved for the same indications as their originator (Humira ^®). However, data on their efficacy and safety in children with psoriasis are scarce.</p><p><strong>Objective: </strong>To assess the effectiveness and safety of adalimumab biosimilars in a group of adalimumab-naïve patients and another group of patients who switched from originator adalimumab to biosimilars. The co-primary endpoints were the PASI absolute mean, PASI 75, and PASI 90 at 16, 24 and 52 weeks.</p><p><strong>Methods: </strong>In this 52-week, multi-center, non-interventional, observational, retrospective study, patients starting biosimilars in routine practice after January 2022 were enrolled at 10 sites across Italy, Portugal, and France. Disease activity scores such as the Psoriasis Area Severity Index (PASI) and safety data were captured during 12 months following adalimumab biosimilar initiation.</p><p><strong>Results: </strong>A total of 102 pediatric patients with psoriasis receiving adalimumab biosimilar therapy either as naïve (n = 72) or switching from originator adalimumab (n = 30) were enrolled. Median absolute PASI remained low at weeks 16, 24, and 52 in both groups (naïve 5.4, 4.3, 2.8; switching 2.6; 2.0; 1.4 respectively). PASI 75 response at weeks 16, 24, and 52 was observed in 41.7, 55.0, and 77.8% of patients in the naive group and 82.8%, 86.2%, and 92.6% of patients in the switch group. PASI 90 response at weeks 16, 24, and 52 was achieved by 23.3%, 26.7%, and 46.3% of patients in the naïve group and 58.6%, 65.5%, and 55.6% of patients in the switch group. Three patients discontinued biosimilars after the switch due to loss of efficacy. No emergency room visits or hospitalizations were observed during the study period and none of the patients experienced serious adverse effects.</p><p><strong>Conclusion: </strong>Adalimumab biosimilars showed a favorable effectiveness/safety profile in childhood psoriasis. Switching from reference adalimumab to biosimilars did not impact effectiveness and safety. A likelihood of discontinuation was noted in patients who switched from Humira to biosimilars.</p>","PeriodicalId":74589,"journal":{"name":"Psoriasis (Auckland, N.Z.)","volume":"15 ","pages":"233-241"},"PeriodicalIF":5.2,"publicationDate":"2025-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144562288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}